These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9974416)

  • 1. Phenotype and genotype expression in pseudohomozygous factor VLEIDEN : the need for phenotype analysis.
    Kalafatis M; Bernardi F; Simioni P; Lunghi B; Girolami A; Mann KG
    Arterioscler Thromb Vasc Biol; 1999 Feb; 19(2):336-42. PubMed ID: 9974416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased tissue factor-initiated prothrombin activation as a result of the Arg506 --> Gln mutation in factor VLEIDEN.
    van 't Veer C; Kalafatis M; Bertina RM; Simioni P; Mann KG
    J Biol Chem; 1997 Aug; 272(33):20721-9. PubMed ID: 9252393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of the factor VLeiden mutation among autopsy patients with pulmonary thromboembolic disease using an improved method for factor VLeiden detection.
    Gorman TE; Arcot AN; Baker P; Prior TW; Brandt JT
    Am J Clin Pathol; 1999 Mar; 111(3):413-7. PubMed ID: 10078118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: an insight into the APC-resistance assay.
    Kalafatis M; Haley PE; Lu D; Bertina RM; Long GL; Mann KG
    Blood; 1996 Jun; 87(11):4695-707. PubMed ID: 8639839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrimination between normal wildtype and carriers of coagulation factor V Leiden mutation by the activated protein C resistance test in the presence of factor V deficient plasma.
    Reuner KH; Litfin F; Patscheke H
    Eur J Clin Chem Clin Biochem; 1997 Jan; 35(1):41-5. PubMed ID: 9156566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V.
    Castaman G; Lunghi B; Missiaglia E; Bernardi F; Rodeghiero F
    Br J Haematol; 1997 Nov; 99(2):257-61. PubMed ID: 9375735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in hemostasis system in patients with hereditary thrombophilia caused by mutation of blood coagulation factor V ( factor V Leiden)].
    Papaian LP; Kobilianskaia VA; Sheĭdina AM; Baranovskaia SS; Sirotkina OV; Kargin VD; Saltykova NB; Beliazo OE; Golovina OG; Papaian KA; Tarkovskaia LR
    Ter Arkh; 2001; 73(7):47-51. PubMed ID: 11523408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No evidence for an increased risk of venous thrombosis in patients with factor V Leiden by the homozygous 677 C to T mutation in the methylenetetrahydrofolate-reductase gene.
    Rintelen C; Mannhalter C; Lechner K; Eichinger S; Kyrle PA; Papagiannopoulos M; Schneider B; Pabinger I
    Blood Coagul Fibrinolysis; 1999 Mar; 10(2):101-5. PubMed ID: 10192659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.
    Brugge JM; Simioni P; Bernardi F; Tormene D; Lunghi B; Tans G; Pagnan A; Rosing J; Castoldi E
    J Thromb Haemost; 2005 Dec; 3(12):2695-702. PubMed ID: 16359508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of the Factor V Leiden Mutation Arg534Gln in Western Region of Saudi Arabia: Functional Alteration and Association Study With Different Populations.
    Athar M; Abduljaleel Z; Ghita IS; Albagenny AA; Halawani SH; Alkazmi MM; Elbjeirami WM; Alquthami K; Alkhuzae MM; Ragab FM; Al-Allaf FA
    Clin Appl Thromb Hemost; 2021; 27():1076029620978532. PubMed ID: 33448877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A matrix-assisted laser desorption/ionization time-of-flight based method for screening the 1691G --> A mutation in the factor V gene.
    Hung K; Sun X; Ding H; Kalafatis M; Simioni P; Guo B
    Blood Coagul Fibrinolysis; 2002 Mar; 13(2):117-22. PubMed ID: 11914653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of factor V levels in plasma by polymorphisms in the C2 domain.
    Scanavini D; Girelli D; Lunghi B; Martinelli N; Legnani C; Pinotti M; Palareti G; Bernardi F
    Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):200-6. PubMed ID: 14656739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis.
    Castaman G; Tosetto A; Ruggeri M; Rodeghiero F
    Br J Haematol; 1999 Jul; 106(1):232-6. PubMed ID: 10444192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arterial and venous thrombosis in two Italian families with the factor V Arg506-->Gln mutation.
    Montaruli B; Voorberg J; Tamponi G; Borchiellini A; Muleo G; Pannocchia A; van Mourik JA; Schinco P
    Eur J Haematol; 1996 Jul; 57(1):96-100. PubMed ID: 8698138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
    Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
    Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor VLeiden.
    Bajzar L; Kalafatis M; Simioni P; Tracy PB
    J Biol Chem; 1996 Sep; 271(38):22949-52. PubMed ID: 8798478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do incident and recurrent venous thromboembolism risks truly differ between heterozygous and homozygous Factor V Leiden carriers? A retrospective cohort study.
    Perez Botero J; Ormsby WD; Ashrani AA; McBane RD; Wysokinski WE; Patnaik MM; Lewis BR; Grill DE; Pruthi RK; Heit JA
    Eur J Intern Med; 2016 May; 30():77-81. PubMed ID: 26970916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations.
    Kalafatis M; Simioni P; Tormene D; Beck DO; Luni S; Girolami A
    Blood; 2002 Jun; 99(11):3985-92. PubMed ID: 12010798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
    de Visser MC; Guasch JF; Kamphuisen PW; Vos HL; Rosendaal FR; Bertina RM
    Thromb Haemost; 2000 Apr; 83(4):577-82. PubMed ID: 10780320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients.
    Födinger M; Mannhalter C; Pabinger I; Koizar D; Rintelen C; Hörl WH; Sunder-Plassmann G
    Nephrol Dial Transplant; 1996 Apr; 11(4):668-72. PubMed ID: 8671856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.